Phase 1 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with an advanced or spreading solid tumour (not including colorectal/bowel cancer)
- People whose disease can be measured using standard imaging criteria (known as RECIST version 1.1)
- People whose tumour has a specific genetic change called a BRAF V600 mutation
- People who have already received certain prior treatments, depending on their tumour type (confirm with trial site)
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements (confirm with trial site)
Who may not be able to join:
- People who have had another active cancer within the past 3 years
- People who have cancer that has spread to the membranes surrounding the brain or spinal cord
- People with a history of, or current, blockage of a vein in the retina (back of the eye), or a history of a degenerative disease affecting the retina
- People who have a nerve or muscle disorder that causes elevated levels of a specific muscle enzyme called creatine kinase
- People with certain active digestive tract conditions, as defined by the trial's specific guidelines (confirm with trial site)
- People with a history of a lung condition involving scarring or inflammation of the lung tissue, as defined by the trial's specific guidelines (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs); Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with treatment-emergent adverse events (AEs); Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in laboratory abnormalities; Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with clinically significant change from baseline in vital sign abnormalities; Phase 1a monothe...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.